LENZ Therapeutics LENZ
NASDAQ LENZ
$4.11 +0.01 (+0.24%)
At close: Nov 11, 2026 · 4:00 PM EST

LENZ Therapeutics (LENZ) Current Deferred Revenue (2026)

Updated

LENZ Therapeutics (LENZ) posted Current Deferred Revenue of $785,000 for Q2 2026.

Analysis

LENZ Therapeutics (LENZ) Current Deferred Revenue (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 LENZ Therapeutics 128.82 Mn -839.21 Mn 2.93 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 785,000.00
API Access

LENZ Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=LENZ&period=max&api_key=YOUR_API_KEY